Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ): HQ2216 obtains clinical trial approval.
Bai Cheng Pharmaceutical (301096.SZ) announcement, the company's wholly-owned subsidiary Bai Cheng Pharmaceutical (Zhuhai Hengqin) Co., Ltd....
Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) announced that its wholly-owned subsidiary, Hangzhou Bio-Sincerity Pharma-Tech (Zhuhai Hengqin) Co., Ltd., recently received a clinical trial approval notification from the National Medical Products Administration (NMPA). The company's independently developed drug HQ2216 will undergo clinical trial research for the prevention of stress-induced ulcer bleeding in critically ill patients.
Related Articles
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
